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OBJECTIVES: In children, coronavirus disease 2019 is usually mild but 
can develop severe hypoxemic failure or a severe multisystem inflamma-
tory syndrome, the latter considered to be a postinfectious syndrome, with 
cardiac involvement alone or together with a toxic shock like-presentation. 
Given the novelty of severe acute respiratory syndrome coronavirus 2, the 
causative agent of the recent coronavirus disease 2019 pandemic, little is 
known about the pathophysiology and phenotypic expressions of this new 
infectious disease nor the optimal treatment approach.
STUDY SELECTION: From inception to July 10, 2020, repeated PubMed 
and open Web searches have been done by the scientific section collab-
orative group members of the European Society of Pediatric and Neonatal 
Intensive Care.
DATA EXTRACTION: There is little in the way of clinical research in chil-
dren affected by coronavirus disease 2019, apart from descriptive data 
and epidemiology.
DATA SYNTHESIS: Even though basic treatment and organ support con-
siderations seem not to differ much from other critical illness, such as pedi-
atric septic shock and multiple organ failure, seen in PICUs, some specific 
issues must be considered when caring for children with severe corona-
virus disease 2019 disease.
CONCLUSIONS: In this clinical guidance article, we review the current 
clinical knowledge of coronavirus disease 2019 disease in critically ill chil-
dren and discuss some specific treatment concepts based mainly on ex-
pert opinion based on limited experience and the lack of any completed 
controlled trials in children at this time.
KEY WORDS: children; coronavirus; hypoxemic respiratory failure; 
multisystem inflammatory syndrome, pediatric intensive care 
Coronavirus disease 2019 (COVID-19) caused by severe acute respira-tory syndrome coronavirus 2 (SARS-CoV2) is usually mild in children, few require hospitalization and/or intensive care (1, 2), and death is 
rare (3). Like in adults, it is mainly, but not obligatorily, characterized by respi-
ratory illness, fever, flu-like or abdominal symptoms, including diarrhea (1, 4).
Respiratory involvement varies from mild upper respiratory tract symp-
toms to severe acute respiratory distress syndrome (ARDS). Gattinoni et al (5) 
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proposed two adult ARDS phenotypes of COVID-19 
that may coexist: “Type L COVID-19 ARDS” char-
acterized by intrapulmonary shunting, preserved 
compliance, less potential for lung recruitability, and 
increased alveolar dead space due to pulmonary micro-
thrombi formation; “Type H”, a more “traditional” 
ARDS characterized by low compliance. These phe-
notypes have not been described in children, although 
some with multisystem inflammatory syndrome (MIS) 
(see below) show reduced lung compliance but near 
normal oxygenation (PC Rimensberger, unpublished 
observations, 2020 and reported by Chao [6]).
Recently, Pediatric MIS-Temporally associated with 
COVID-19 (PIMS-TS, later termed MIS-C in the 
United States and MIS by World Health Organization, 
which we use in this international article) has been re-
ported (7–12). It is unknown if MIS is a postinfectious 
immune reaction with aberrant development of ac-
quired immunity or a novel disease (11, 12).
A prodrome of lethargy and high temperature, with 
half reporting acute abdominal pain and diarrhea, is 
followed by a marked inflammatory multisystemic 
syndrome with either 1) a refractory “toxic” shock-
like (TSS) syndrome with predominantly vasoplegic 
or cardiogenic shock or 2) a Kawasaki-like syndrome 
including coronary dilatation/aneurysms or a combi-
nation of both. MIS can occasionally be the “initial” pre-
sentation of COVID-19 (7, 9). Respiratory symptoms 
may not be present (11). Increased C-reactive protein, 
interleukin (IL) 1 and 6, mild to moderately elevated 
troponin, and high pro-BNP can be found (8–11).
This European Society of Pediatric and Neonatal 
Intensive Care (ESPNIC) statement provides recom-
mendations for caring for children with suspected or 
proven SARS-CoV2 in intensive or intermediate care 
units. It builds on previous ESPNIC statements or con-
sensus paper recommendations (13) unless otherwise 
stated, including pediatric guidance on septic shock 
(14), acute lung injury (15), noninvasive and invasive 
mechanical ventilation (16, 17), extracorporeal respira-
tory and/or circulatory support (extracorporeal mem-
brane oxygenation [ECMO]) (18, 19), acute kidney 
injury (AKI) (20), nutrition (21, 22), Kawasaki disease 
(KD) (23), and emergency mass critical care (24).
METHODOLOGY
The ESPNIC scientific group collaborative (two lead-
ing/writing members per section) worked with a 
4-week timeline to draft recommendations. Given the 
paucity of pediatric COVID-19 outcome studies, the 
National Institutes of Health (NIH) consensus state-
ment standards and Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) 
approach are not yet suitable (25).
Main PubMed search terms for repeated searches 
included coronavirus, COVID-19, SARS-CoV2, crit-
ical-illness, children, Kawasaki-like disease, MIS/
PIMS-TS & MIS-C, and terms related to each section 
topic. Section leads selected section members based 
on their expertise for advice and validation of drafted 
recommendations. The authors (P.C.R., M.C.J.K., J.B.) 
coordinated the work and edited draft recommenda-
tions. Each modification was sent back to section leads 
for final approval.
Basic Rules—Protect Yourself and Your Team
One or repeated nasal swab specimen negative poly-
merase chain reaction may occur and does not rule out 
COVID-19 (26). Thus, full personal protective equip-
ment (PPE) should always be worn when caring for 
COVID-19 positive or suspected children. Aerosol-
generating procedures (AGPs) (Table 1) are high-risk 
interventions and must be reduced to an absolute 
minimum.
Respiratory Illness and Support
Pediatric Acute Lung Injury Consensus Conference 
and Pediatric Mechanical Ventilation Consensus 
Conference recommendations on respiratory support 
modes, strategies, and pulmonary ancillary treatment 
apply (15, 16). Of note, there is an increased risk of 
air-borne disease dissemination using noninvasive 
respiratory support (Table 2). Ideally, an adequate in-
terface seal should be assured (e.g. helmet, nonvented 
oronasal or full-face mask) (27). Bacterial/viral filters 
(high-efficiency particulate air filter) must be placed at 
least on the expiratory limb of the patient circuit for 
invasive and noninvasive mechanical ventilation.
Delayed intubation is usually avoided in children with 
marked hypoxic-respiratory failure (Spo2/Fio2 < 221) 
or with no improvement with NIV within 60–90 min-
utes (16, 17). However, higher intubation thresholds 
may be reasonable in proven COVID-19 hypoxic res-
piratory failure with low work of breathing and/or no 
pathologic hyperventilation.
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Intubation should be performed by an expert in 
airway management in a closed environment with 
minimal staff present. Video laryngoscopy, rapid 
sequence induction, and avoiding bag/mask venti-
lation are recommended (28). If bag/mask ventila-
tion cannot be avoided, the “two-person technique” 
is preferable to ensure better mask seal. Cuffed en-
dotracheal tube should be used irrespective of pa-
tient age.
Measuring the quasi-static respiratory system com-
pliance (Crs) under zero flow conditions after intuba-
tion, and then daily, allows identification of the clinical 
phenotype (i.e. with preserved or decreased Crs) and 
guides ventilator settings (Table 3).
Microvascular Pulmonary Thrombosis, 
Pulmonary Embolism, and Thromboprophylaxis
Hypercoagulability, common in adults with COVID-
19, has been observed in severely affected children, 
in whom we recommend a daily coagulation screen 
(d-dimer, prothrombin time, platelet count) (33) and 
pharmacologic thromboprophylaxis with either low 
weight molecular weight or unfractionated heparin 
(34)—based on renal function (creatinine clearance 
cut off value 30 mL/min).
In children with refractory hypoxia or right heart 
strain on electrocardiogram/echo, inferior vena cava 
signs, or raised d-dimers, we recommend screening 
for pulmonary embolism (PE) (e.g. ultrasound and/
or CT-angiogram) and if found aggressive treatment: 
systemic anticoagulation is first line, but consider sys-
temic thrombolysis or interventional radiology after 
multidisciplinary consultation for PE-induced hemo-
dynamic compromise (34).
Cardiovascular Involvement
There is no change to the 2020 Surviving Sepsis 
Campaign (SSC) “pediatric septic shock guidance” 
(14) recommended in children with COVID-19. Of 
note, hypovolemia is common following the vomiting 
and diarrheal prodrome with reduced fluid intake be-
fore ICU admission.
Specific MIS treatment (Fig. 1) should follow a 
multidisciplinary approach involving infectious dis-
eases specialists, rheumatologists, cardiologists, and 
TABLE 1. 
Common Aerosol-Generating Events
 High-flow nasal cannula.
 Continuous positive airway pressure or noninvasive 
ventilation without an adequate seal.
 Bag-mask ventilation.
 Intubation.
 Any advertent or inadvertent circuit or endotracheal 
tube disconnection.
 Tracheal suction (without a closed system).
 Extubation.
 Coughing/sneezing or any procedure inducing this.
 Chest physiotherapy.
 Delivery of nebulized medications (unless via 
closed circuit).
 Cardiopulmonary resuscitation (prior to 
intubation).
TABLE 2. 
General Recommendations for Patients 
Requiring Respiratory Support
 Strict personal protection equipment is 
mandated when managing patients, especially 
when handling airways, with suspected or 
confirmed coronavirus disease 2019.
 Assure an adequate seal of the interphase for 
noninvasive ventilation.
 Use cuffed ETTs for invasive ventilation.
 Use bacterial/viral filters (high-efficiency particu-
late air filter) on the expiratory limb of the patient 
circuit.
 Minimize ETT disconnections and use inline, 
closed suctioning.
 Use airway humidification (active or passive), 
beware of endotracheal tube occlusion due to 
plugging caused by tenacious secretions.
 Supportive care: fluid management, 
hemodynamic management, transfusion 
strategies, nutritional management, and 
sedation and analgesia practices should also 
be applied per Pediatric Acute Lung Injury 
Consensus Conference recommendations.
ETT = endotracheal tube.
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TABLE 3. 
Practice Recommendation for Coronavirus Disease 2019 Children on Invasive 
Mechanical Ventilation
Ventilator settings Initial settings
 Vt–expiratory 5–7 mL/kg ideal bodyweight, lower Vt may be targeted if decreased lung compliance.
 PEEP and Fio2 Initial PEEP ± 8–10 cm H2O
a—further increase based on guidance from the low PEEP/Fio2 
grid (29)b.
 Titration of PEEP/Fio2 to maintain oxygen saturation 92–96% for moderate or 88–92% for 
severe pediatric acute respiratory distress syndrome
Goals and limits Values
 Driving pressure ≤ 15 cm H2O
 Pplat < 28–32 cm H2O
 pH > 7.20
Supportive measures Specific recommendation
 Neuromuscular  
 blockade
Consider early use of neuromuscular blocking agents for 24–48 hr if Pao2/Fio2 < 150;  
OI ≥ 16; OSI ≥ 10, and/or if there is spontaneous breathing at high (esophageal) trans-
pulmonary pressures, minimizing ventilator dyssynchrony, prone positioning, and avoid-
ing high Pplat.
 Prone positioning Consider early use of neuromuscular blocking agents for 24–48 hr if Pao2/Fio2 < 150;  
OI ≥ 16; OSI ≥ 10, especially if there is concomitant reduced lung compliance.
Escalating therapies  
  for refractory 
hypoxemia
Proposed clinical approach
 PEEP/recruitment Titrate PEEP, balancing oxygenation, and hemodynamics. High PEEP may be necessary if 
low lung compliance.
 iNO Use iNO if documented pulmonary hypertension and/or right ventricular dysfunction/failure.
 Consider iNO if alteration in hypoxic pulmonary vasoconstriction is presumed (i.e. lack of 
improvement in oxygenation despite all other measures).
 With acute onset of marked hypoxemia consider pulmonary embolism (d-dimers, ultra-
sound, CT thorax).
 HFOV HFOV may be considered in patients with poor lung compliance (i.e. requiring inspiratory airway 
pressures during conventional mechanical ventilation of 30 cm H2O or higher to maintain ac-
ceptable ventilation ([i.e. pH > 7.20]) and/or oxygenation despite adequate PEEP settings.




May be considered if refractory hypoxemia persists despite all measures used.
HFOV = high-frequency oscillatory ventilation, iNO = inhaled nitric oxide, OI = oxygenation index, OSI = oxygen saturation index,  
PEEP = positive end-expiratory pressure, Pplat = plateau pressure, Vt =     tidal volume.
a Lower initial PEEP levels should be considered in patients with preserved compliance (“Type L” lung disease [5]) indicating “non”-
recruitable lung disease.
b    PEEP levels below the PEEP/Fio2 grid have shown to be associated with increased mortality in pediatric acute respiratory distress 
syndrome (32).
Feature Article
Pediatric Critical Care Medicine www.pccmjournal.org     5
intensivists. In Kawasaki-like or TSS presentations (e.g. 
hyperinflammatory shock) especially when myocar-
dial dysfunction is documented, successful use of IV 
immunoglobulin administered early as per KD guide-
lines (23) has been reported (9–11) and can be recom-
mended, acknowledging this is not based on data for 
the TSS-like presentation. Besides IVIG, steroids are 
the most frequently used anti-inflammatory drug (8–
11). In the event of resistance to IVIG and persistent 
high inflammatory markers, anti-IL-6 monoclonal 
antibody (Tocilizumab, Sarilumab), IL-1 receptor an-
tagonist (Anakinra), or tumor necrosis factor-α antag-
onist (Infliximab) has been used on an empirical basis 
(9, 11). However, according to NIH COVID-19 treat-
ment guidelines (July 17, 2020), there are insufficient 
data yet to recommend for or against the use of either 
IL-6 or IL-1 inhibitors (35).
In cardiovascular compromise/hemodynamic in-
stability, repeated multimodal hemodynamic moni-
toring, including point of care ultrasound (36), can 
optimize therapy. With documented myocardial and/
or coronary involvement, serial and follow-up echo-
cardiography by a pediatric cardiologist is important 
and might allow for an eventual better understanding 
of this novel disease for which the Initial early prog-
nosis seems good (9).
COVID-19 is not a contraindication to ECMO in 
children, the present indications and thresholds for 
ECMO as per currently published extracorporeal life 
support organization (ELSO) guidelines apply (18). 
Shock refractory to standard management should 
prompt early consultation with ECMO providers (19) 
although specific COVID-19 ECMO data in the con-
text of MIS are sparse (9, 11). In line with interim ELSO 
Figure 1. Proposed specific treatment options (beyond basic ICU treatment concepts) for coronavirus disease 2019 (COVID-19)–
related severe respiratory disease (SARS) and multisystem inflammatory syndrome (MIS). ARDS = acute respiratory distress syndrome, 
BNP = brain natriuretic peptide, CRP = C reactive protein, CoV2 = coronavirus 2, KD = Kawasaki disease, IgG = immunoglobulin 
G, IL = interleukin, IVIG = IV immunoglobulin, LMWH = low molecular weight heparin,  LV = left ventricular, TNF-a = tumor necrosis 
factor-alpha.
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COVID-19 guidelines (18), we do not recommend ex-
tracorporeal cardiopulmonary resuscitation outside an 
ICU setting and without an experienced team.
AKI and Renal Replacement Therapies 
Although the epidemiology and etiology of COVID-19 
AKI may differ slightly from other types of critical ill-
ness, management is essentially the same (20). Unless 
there is a situation such as severe sepsis where con-
tinuous renal replacement therapy (CRRT) is clearly 
superior to peritoneal dialysis (PD) allowing hemody-
namic stability and more accurate fluid removal (37), 
both methods are equally efficacious (38).
Given the COVID-19 cytokine storm, other extra-
corporeal therapies (e.g. hemoperfusion and cytoab-
sorption) have been proposed in COVID-19 ICU 
patients with AKI to remove proinflammatory cyto-
kines (39), thereby reducing cytokine storm induced 
organ damage. With minimal supportive data and the 
risk of therapeutic drug removal, as well as poor avail-
ability, we do not currently recommend them.
Adaptation of Renal Replacement Therapy 
Regimens With Resource Limitation. With resource 
limitations, renal replacement therapy (RRT) regimens 
can be adapted. 1) Single machine use for two or more 
patients by increasing exchange rates to compensate 
for decreased RRT time (31). 2) Use of lower rates after 
achieving metabolic control to limit consumable waste 
(32). 3) If CRRT unavailable, PD may be used (38).
Risks of Filter Clotting During CRRT. The hyper-
coagulable COVID-19 state means frequent filter clot-
ting, and vascular thrombosis can be an issue, so the 
usual approach of prefilter heparin is recommended 
(20) (Table 4). Many adults with COVID-19 have had 
deranged liver function tests (LFTs) (40), so citrate has 
been relatively contraindicated. Cautious use in chil-
dren is permitted, although few have had deranged 
LFTs to date. Alternatively, a combination of prosta-
cyclin and unfractionated heparin (both pre filter) can 
be used.
Neurologic Involvement
COVID-19, as with other viral infections, can cause 
rare but important neurologic manifestations in chil-
dren (e.g., meningitis, encephalitis, acute dissemi-
nated encephalomyelitis, postinfectious brainstem 
encephalitis, Guillain-Barre syndrome, myositis, acute 
necrotizing hemorrhagic encephalopathy, and an-
osmia [41–43]).
COVID-19 can present atypically in both adults and 
children with nonspecific neurologic symptoms (e.g. 
headache, dizziness, impairment of taste and smell, 
seizures, neck stiffness, photophobia, altered mental 
state, behavioral changes, and movement disorders 
[9, 11, 43]). Thus, clinicians should consider COVID-19 
TABLE 4. 
Measures to Reduce the Risk of Filter 
Clotting During Continuous Renal 
Replacement Therapy
 Address all issues related to vascular catheter—size, 
location, bending, kinking, leakage.
 Higher blood flow rates and predilution replace-
ment fluid administration reduces the chances of 
clotting of the filter.
 Preferring filters with larger surface area to reduce 
transmembrane pressure.
 While using continuous veno-venous hemodiafil-
tration, reduce the postfilter component to avoid 
clotting in the bubble trap.
 Dose heparin infusion appropriately. Follow 
practical tips from the Kidney Disease Improving 
Global Organization guidelines [18].
 Consider using a heparin bolus 20 U/kg.
 Start prefilter heparin at higher than usual  
rates 20–30 U/kg/hr (usual 10–20 U/kg/hr).
 Maintain ACT 180–220 s, if ACT is low and the 
filter clots- increase the dose by 10–20% of the 
previous dose.
 Heparin 10 U/kg/hr and prostacyclin 4 ng/kg/min 
can be combined as anticoagulants.
 While using citrate regional anticoagulation, aim 
for lower ionized calcium levels in the circuit: 0.2 
mmol/L instead of the usual 0.3–0.4 mmol/L.
 Heparin and citrate can be combined as well. 
Unfractionated heparin is infused directly into 
the patient at a dose of 10 U/kg/hr whilst 
citrate is administered regionally at the usual 
dose –1.5 × blood flow rate (citrate dose might 
have to be increased) with calcium infusion 
(calcium chloride or calcium gluconate).
ACT = activated clotting time.
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in children presenting with new-onset neurologic 
symptoms. Infant COVID-19–associated seizures 
have been reported (44), and current status epilep-
ticus management guidelines should be followed and 
neurophysiologic monitoring considered in high-risk 
patients (45, 46). Hypercoagulable state in COVID-19 
predispose patients to a risk of acute cerebrovas-
cular disease (23) and early neuroimaging with CT or 
MRI in patients with neurologic symptoms will assist 
diagnosis.
Anti-Inflammatory, Antiviral Treatment, and 
Antibacterial Treatment
Evidence for best practice and recommendations 
around antiviral and anti-inflammatory treatment in 
COVID-19 is rapidly evolving, and—given the relative 
rarity of severe COVID-19 presentations in children—
infectious diseases and immunology experts should 
be consulted early and treatments determined by con-
sensus with families. For compassionate use, bioethics 
support is also warranted, and the risk of innovative 
therapy must be fully explained to the family. However, 
if formal clinical trials are available, children should be 
enrolled (47).
Antibacterial Treatment. Critically ill children with 
respiratory or systemic disease are much more likely 
to suffer from bacterial or other viral infections, which 
should be promptly treated as per the SSC guidelines 
even during the COVID-19 pandemic (14). The prin-
cipals of antimicrobial stewardship should be followed.
Anti-Inflammatory Treatment. Consider systemic 
anti-inflammatory treatment (e.g. high-dose steroids) 
in unstable patients with MIS. Immunomodulation (e.g. 
targeted IL-6 antagonists such as Tocilizumab or IL-1 re-
ceptor antagonist [Anakinra]) in patients with hyperex-
pression of several cytokines including IL-6 and IL-1β, 
hyperferritinemia, and thrombocytopenia (i.e. cytokine 
storm) should remain limited to clinical trials (47).
Antiviral Therapies. In severe COVID-19–related 
respiratory illness, empirical antiviral agents can be 
considered, whereas as MIS is likely to be a postinfec-
tious syndrome they should not (11, 12).
Based on adult data, remdesivir is the preferred an-
tiviral drug for compassionate use in children (48). The 
U.S. Food and Drug Administration has authorized it 
as an investigational antiviral drug (emergency use au-
thorization May 1, 2020) (49). Lopinavir/ritonavir, a 
protease inhibitor, may be considered if remdesivir is 
unavailable (50).
Nutritional Support
Usual ICU nutritional practice (21, 22) is recommended. 
Specific COVID-19 aspects are as follows: Enteral feed-
ing tube placement and aspiration are potential AGP so 
1) decrease exposure by quicker gastric tube placement 
rather than postpyloric tubes and 2) avoid measuring 
gastric residual volumes, which has limited evidence.
Neonatal and Pediatric Transport: Specific 
Considerations
Additional recommendations to existing transport poli-
cies for the transport of both suspected and SARS-CoV2 
proven children, either inside or between hospitals, are 
necessary, primarily to protect the team involved.
SARS-CoV2 status of an infant or child must be 
determined at referral, so staff, PPE, and equipment 
can be prepared as well as referring and receiving unit 
secure pathways for the transfer team within the hos-
pital to avoid cross-contamination of clean areas/staff. 
We recommend that the team transporting children 
with suspected/confirmed COVID-19 must wear full 
PPE. For staff (i.e. ambulance drivers, paramedics) 
not directly involved inpatient care but coming into 
their close proximity (< 2 m) (e.g. loading/unloading 
stretcher), at least reduced PPE is mandatory. Patients, 
if self-ventilating, should wear a surgical mask when-
ever feasible to minimize aerosol spread. The risk of 
AGP during transport conditions, with staff wear-
ing full PPE, is greater than in ICU; hence, a lower 
threshold for pretransport intubation to avoid emer-
gency intubation during transport is justified.
For pediatric stretcher transports closed transport 
capsules, if available and the child’s condition allows, 
reduce aerosol spread. Air conditioning/ventilation 
must, if possible, be set to extract to avoid air recircula-
tion. Counterintuitively as it is contrary to family cen-
tered care, infants and children should be transported 
without their parents or relatives present.
At the destination, designated areas must be available 
for PPE doffing by transport staff. After the transport 
exposed transport equipment including equipment 
left in the transport vehicle (i.e. not within closed com-
partments) requires decontamination with a universal 
detergent, followed by cleaning of the entire interior 
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of the vehicle with a chlorine-based solution at 1,000 
parts per million (51).
Nursing Care
Protection of nursing personnel is paramount, with 
full PPE available and used effectively to minimize 
contamination. The primary goals of nursing care must 
be rethought during a pandemic (e.g. organization and 
function of a unit and its staff [24]), with some nursing 
protocols adapted or modified.
The number of caregivers and time in a bed-space can 
be minimized, for example, use of extenders (deployed 
personnel) who remain outside patient’s immediate 
area/dedicated “infectious” zone to prepare drugs, or-
ganize/set-up devices, and communicate between ward 
control/nurse in charge and the bedside nurse.
The use of consumables such as in-line suction 
catheters and ventilator circuits must be considered 
both are able to be used for up to 7 days (52, 53). 
Fundamental nursing care should be clustered (12 hr) 
to reduce nursing exposure and promote physiologic 
stability. This includes eye care, oral care, washing, 
and pressure area prevention to reduce iatrogenic in-
jury (54). Safe and prolonged prone positioning is also 
helpful in pediatric COVID-19 pneumonitis and safer 
using a checklist (55).
The nursing workload model must change from 
usual patient-centered model to task delivery allocation 
ensuring vital care (e.g. proning, medication) is com-
pleted safely and effectively despite fewer qualified staff. 
Reduced nurse:patient ratios place significant stress on 
the whole team, changing standards from “ideal” to 
best possible critical care with the resources available.
Finally, a vital nursing role during COVID-19 
is to promote and optimize family/parent involve-
ment in care despite significantly restricted visitation. 
Consistent daily family communication is essential, 
that is, video-conferencing (56, 57). Reducing the child 
and family’s fear of staff in full PPE is essential, requir-
ing careful developmentally appropriate explanations 
and the use of play (56).
Visiting and Spiritual Care
Restrictions on visiting are at odds with usual PICU 
family-centered care. Families in self-isolation or with 
COVID-19 are usually not permitted into hospitals to 
protect other children, parents/families, and staff from 
infection. In exceptional circumstances, such as immi-
nent or actual bereavement, full PPE can be worn by 
the individuals affected. Otherwise restricted visiting, 
such as one parent and no siblings, has become usual. 
Novel ways to enable contact such as video-conferenc-
ing with boyfriend/girlfriend and school friends should 
be instituted for teenagers. The psychologic distress for 
the parents of critically ill children, compounded by 
the removal of primary support mechanisms, is being 
witnessed by many of us and worthy of formal study. 
The dehumanizing effects of PPE, the absence of rela-
tives, and even personal effects are concerning too. 
Compassionate exceptions to restricted visiting poli-
cies should be considered in specific situations, but the 
risk to healthcare teams is also worrying (58).
Spiritual support should be offered on request given 
that as religion and spirituality provide the foundation 
for many people’s morality. Consultation with faith or 
nonfaith (philosophical, psychologic or pastoral) sup-
port must be offered and can include religious rites 
performed by video link. Faith/spiritual/other sup-
portive care must also be available for staff, particularly 
those struggling with the dehumanizing aspect and the 
tough decisions being made and their results.
Ethical Considerations
The COVID-19 triaging decisions required by “adult” 
colleagues have not been necessary in children with 
their lower disease severity. It is worth noting the com-
plex pediatric population may become an issue in an-
other pandemic or even a second wave (59).
Rather than direct infection, the COVID-19 ethical 
issues affecting children and PICU teams are the loss 
of other healthcare opportunities with major cancelled 
surgery, clinics and other issues, social isolation, and 
education issues, and for staff, PPE availability, reduced 
parent presence with sick children, and moral injury to 
those deployed to adult services who have seen/made 
rapid existential decisions.
Difficult treatment decisions during a pandemic 
must comply with relevant ethical principles, and in-
dependent ethics support must be available for both 
clinicians and families (60).
CONCLUSIONS
COVID-19 in children has been thought to be mild 
and mainly, yet not obligatory, characterized by 
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respiratory illness, fever, flu-like symptoms, and 
only rarely progressing to severe hypoxic-respiratory 
failure. However, recently the MIS was described in 
children, although whether this represents an acute 
inflammatory manifestation of COVID-19, a postin-
fectious immune reaction or different disease remains 
unclear. Suitable registries are urgently required for 
this purpose.
The majority of our recommendations for children 
with COVID-19 are essentially the same as for any 
critically ill child, for example, noninvasive or invasive 
mechanical ventilation, cardiac failure, pediatric sepsis, 
and multiple organ failure. We have highlighted those 
areas where there is enough clinical experience or spe-
cific concern to amend current recommendations.
Many involve the risk to staff, for example, PPE 
and transport and reduced staff and family numbers 
in PICU. Anti-inflammatory and infective approaches, 
for example, immunomodulation and antiviral thera-
pies, are suggested but are largely considered on a 
compassionate basis as controlled studies do not exist.
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